Home
    • Plans Blog Contact
    Eton Pharmaceuticals Inc logo

    Eton Pharmaceuticals Inc

    ETON
    Last price US$58.52
    Market cap US$1.0b
    12M price change 250.00%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Eton Pharmaceuticals Inc Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis; Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis; EPRONTIA, a liquid formulation of topiramate; ZONISADE, a liquid formulation of zonisamide for the treatment of partial seizures in patients with epilepsy; and Lamotrigine for Oral Suspension for the treatment of epilepsy. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Ac Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Eton Pharmaceuticals Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 13, 2026

    Quarterly result summary

    Revenue was $37.6M (+99% YoY); EPS was $0.43 (reported).

    Revenue $37.6M +99% YoY
    EPS $0.43 reported
    Net income $14.3M reported
    Adjusted EBITDA $14.1M reported

    What changed

    • Revenue +99% YoY to $37.6M; EPS reported to $0.43.

    Guidance / outlook

    The Company expects full year 2026 adjusted gross margin to exceed 70%, inclusive of the potential $4 million commercial milestone referred to above.

    Earnings material Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 10-Q Aug 13, 2026 SEC filing FORM 8-K Aug 13, 2026 SEC filing FORM 8-K May 14, 2026 SEC filing FORM 10-Q May 14, 2026 Earnings release EXHIBIT 99.1 May 14, 2026 SEC filing FORM 8-K Mar 19, 2026 SEC filing FORM 10-K Mar 19, 2026 Earnings release EXHIBIT 99.1 Mar 19, 2026 SEC filing FORM 10-Q Nov 06, 2025 SEC filing FORM 8-K Nov 06, 2025 Earnings release EXHIBIT 99.1 Nov 06, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Eton Pharmaceuticals Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 1.50/5
    Eton Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Eton Pharmac... ETON US$1.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.98/5
    Eton Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Eton Pharmac... ETON US$1.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 2.21/5
    Eton Pharmaceuticals Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Eton Pharmac... ETON US$1.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Eton Pharmaceuticals Inc logo

    Eton Pharmaceuticals Inc

    US$58.52

    US$6.19

    -89.4% vs price

    US$1.0b

    31.36%

    250.00%